Kodiak Sciences discontinues development of eye disorder therapeutic; shares plummetProactive Investors • 07/24/23
Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatmentMarket Watch • 07/24/23
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development ProgramPRNewsWire • 07/24/23
Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?Zacks Investment Research • 06/14/23
Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business HighlightsPRNewsWire • 05/15/23
Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?Zacks Investment Research • 04/27/23
Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual MeetingPRNewsWire • 04/21/23
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema StudyZacks Investment Research • 04/04/23
Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal DiseasesPRNewsWire • 04/03/23
Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business HighlightsPRNewsWire • 03/28/23
Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual MeetingPRNewsWire • 02/09/23
Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/09/22
Does Kodiak Sciences Inc. (KOD) Have the Potential to Rally 87% as Wall Street Analysts Expect?Zacks Investment Research • 11/30/22
Wall Street Analysts See a 72% Upside in Kodiak Sciences Inc. (KOD): Can the Stock Really Move This High?Zacks Investment Research • 11/14/22
Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business HighlightsPRNewsWire • 11/09/22